Caesars Entertainment misses Q2 earnings expectations, shares edge lower
On Monday, Cantor Fitzgerald reiterated an Overweight rating on Nyxoah SA (NASDAQ:NYXH) with a steady price target of $14.00. The reaffirmation came after Nyxoah reported its first-quarter financial results for the year 2025 and provided updates on the company’s progress. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $12 to $14.
Nyxoah, which specializes in medical technologies for treating sleep apnea, disclosed its 1Q25 earnings with revenues amounting to $1.1 million. This figure fell short of Cantor Fitzgerald’s projection of $2.4 million and was below the FactSet consensus estimate of $1.6 million. The reported revenue signifies a year-over-year decline of approximately 15%, which has been attributed primarily to the company’s performance in Germany, where it generated nearly all of its revenue. InvestingPro analysis reveals the company’s trailing twelve-month revenue stands at $4.72 million, with several ProTips highlighting both challenges and opportunities ahead.
The company also experienced a slight dip in gross margins, which decreased to around 61.8% in the quarter, down from roughly 62.7% in the same period the previous year. Additionally, Nyxoah saw a significant increase in total operating expenses, which surged by about 61% year-over-year to $22.5 million.
The financial results highlight the challenges Nyxoah faces in its operational markets, particularly in Germany. Despite the decline in revenue and gross margins coupled with rising operating expenses, Cantor Fitzgerald’s analyst Ross Osborn maintains confidence in the stock’s potential, as reflected in the unchanged Overweight rating and price target.
In other recent news, Nyxoah has received attention from several analyst firms regarding its Genio system, a device aimed at treating obstructive sleep apnea. Stifel analysts recently adjusted their price target for Nyxoah from $15 to $14, maintaining a Buy rating, following the receipt of an "approvable" letter from the FDA. This letter indicates a delay in full approval, with expectations now set for the third quarter of 2025. Oppenheimer also reaffirmed its Outperform rating with a $13 price target, highlighting ongoing discussions with the FDA about the company’s manufacturing processes. H.C. Wainwright maintained its Buy rating with a $17 target, noting that Nyxoah’s fourth-quarter sales for the Genio system were €1.3 million, with deferred revenues potentially increasing this figure to €1.9 million.
Despite the challenges, analysts remain optimistic about Nyxoah’s future. Stifel anticipates the Genio system will drive growth in the sleep apnea industry, and its labeling could offer competitive advantages over competitors. The company has already trained over 75 U.S. physicians in preparation for a potential U.S. launch. H.C. Wainwright forecasts Genio sales to reach €15.0 million in 2025, considering anticipated sales in Europe and upcoming U.S. sales. Nyxoah has also launched the Genio system in the UK and announced its introduction to the Middle Eastern market, indicating plans for further international expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.